Pulmonary Surfactant Market, by Type (Synthetic Pulmonary Surfactant,Animal Derived Surfactant), by Drug Type (Poractant alfa, Lucinactant, Calfactant), by Indications (Respiratory Distress Syndrome (RDS), Respiratory Infections, Obstructive lung Diseases, Others(chronic lung disease of prematurity, and surfactant protein-B deficiency)), by Route of Administration (Intratracheal, Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022

Code : CMI5324

Pages :161

Formats :

Excel and PDF

Industry : Biotechnology

Pulmonary Surfactant MarketSize and Trends

Global pulmonary surfactant market size was valued at US$ 578.7 million in 2022 and is expected to witness a CAGR of 4.50 % over the forecast period (2022 – 2030).

Figure 1.Global Pulmonary Surfactant Market Share (%), by Type, 2022

Figure 2.Global Pulmonary Surfactant Market Share (%), by Region, 2022

Increasing prevalence of respiratory infections are attributing to the highest share of North America market in the global pulmonary surfactant market.

Increasing prevalence of the respiratory infections in the U.S. is expected to drive market growth over the forecast period. For instance, in June 2021, The Centers for Disease Control and Prevention, a national public health agency of the U.S. stated that each year in the U.S., RSV (Respiratory Syncytial Virus) leads to on average approximately 58,000 hospitalizations with 100-500 deaths among children younger than 5 years old and 177,000 hospitalizations with 14,000 deaths among adults aged 65 years or older. Infants, young children, and older adults with chronic medical conditions are at risk of severe disease from RSV infection

Global Pulmonary Surfactant Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.The sudden outbreak of COVID-19 has bought the world to a standstill.

Increasing research and development between the key market players of pulmonary surfactant market during COVID-19 pandemic is expected to drive the market growth over the forecast period. For instance, on March 22, 2022, Windtree Therapeutics, Inc., a biotechnology company multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced results from its Phase 2 study of lucinactant (KL4 surfactant) for patients with severe COVID-19 associated acute respiratory distress syndrome (ARDS) and lung injury. The objective for the study was that the SARS-CoV-2 virus causing COVID-19 uses the angiotensin-converting enzyme 2 (ACE2) receptor for entry into host cells. The Phase 2 trial was designed to assess feasibility, safety, and tolerability of administration of reconstituted lyophilized lucinactant in these critically ill patients.